Table 3.

Clinical Studies of TCR-T cells against AML (CML: chronic myeloid leukemia; CRS: cytokine release syndrome; MDS: myelodysplastic syndrome; TCR-T: T cell receptor T cell; WT-1: Wilms’ tumor-1).

Study	TCR-T Therapy	Study Phase/Number of Patients	Study Outcomes	Adverse Events
NCT02550535	Autologous WT1 TCR-T cells	Phase I/II, 10 patients (6 AML, 3 MDS and 1 TKI-resistant CML)	All 6 AML patients were alive at last follow up (median 12 months; range: 7–12.8 months). The 3 patients with MDS had a median survival of 3 months (range: 2.1–3.96 months). Two died from progressive disease and one from other causes. Two patients had disease progression.	1 CRS
UMIN00001159	Autologous WT1 siTCR-T cells	Unknown	Two patients showed transient decrease in blast counts.	None
NCT01640301	Allogeneic WT1 TCR-T cells	Phase I/II, 12 patients	With a median follow-up of 44 months (range: 21–57 months) following infusion, all 12 patients did not have evidence of disease.	None
NCT03503958	Autologous PRAME TCR-T cells	Phase I	Not posted	Not posted
NCT01621724	Autologous WT1 TCR-T cells	Phase I/II, 7 patients	Not posted	Not posted